REG - Allergy Therapeutics - PDMR Dealings

Allergy TherapeuticsAnnouncement

11/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250711:nRSK6406Qa&default-theme=true

RNS Number : 6406Q  Allergy Therapeutics PLC  11 July 2025

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

Issue of 250,674,403 warrants

 

PDMR Dealings

 

11 July 2025 - Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy vaccines, announces
that it has issued 250,674,403 warrants to subscribe for new ordinary shares
in the Company.

 

As previously announced, pursuant to the terms of the £50 million loan
facility under the facility agreement dated 6 April 2023 with SkyGem
Acquistion Limited (an affiliate of ZQ Capital Management Limited) ("SkyGem")
and Southern Fox Investments Limited ("Southern Fox"), as amended from time to
time, ("the Amended Loan Facility") the Company is required to issue 25
warrants for every £1 drawn under the Amended Loan Facility at an exercise
price of 4 pence per warrant and exercisable on or prior to 15 October 2030.
The Company drew down £10 million under the Amended Loan Facility on 1 May
2025 and is therefore required to issue 175,343,750 warrants to SkyGem and
74,656,250 warrants to Southern Fox in accordance with the terms of the
Amended Loan Facility.

 

As a result of the issuance of the warrants to SkyGem and Southern Fox, the
Company is also required to issue 674,403 warrants with an exercise price of
0.1 pence per warrant to Hayfin Healthcare Opportunities LuxCo S.a.r.l., a
fund advised by Hayfin Capital Management LLP ("Hayfin") pursuant to
anti-dilution rights held by Hayfin under the terms of the warrants issued to
Hayfin in connection with the senior secured loan facility entered into
between it and the Company dated 15 October 2024.

 

Following the issue of the warrants as detailed above, the Company has the
following warrants in issue:

 

 Number of warrants  Percentage (%) of enlarged share capital 1   Exercise price  Date of expiry
 937,500,000         15.97                                        4.0 pence       15 October 2030

 132,278,019         2.25                                         0.1 pence       15 October 2034
 33,333,332          0.57                                         30 pence        28 February 2028

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

 

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com
(mailto:allergytherapeutics@icrhealthcare.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. For more information,
please see www.allergytherapeutics.com (http://www.allergytherapeutics.com/)
.

 

 Notification and public disclosure of transactions by Director/persons
discharging managerial responsibilities ("PDMR") and persons closely
associated with them ("PCA")

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Southern Fox Investments Limited

 2   Reason for the notification
 a)  Position/status                                              Persons closely associated Mr. Anthony Parker, Non-Executive Director of
                                                                  Allergy Therapeutics Plc.
 b)  Initial notification/Amendment                               Initial notification.
 3   Details of the issuer, UK emission allowance market participant, auction
     platform or auctioneer
 a)  Name                                                         Allergy Therapeutics Plc
 b)  LEI                                                          213800PQ7AHK7KGVOE23
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Warrant Instrument

 b)  Nature of the transaction                                    Issue of warrants representing subscription rights for ordinary shares of
                                                                  £0.001 each.

 c)  Price(s) and volume(s)                                       Exercise Price(s)                      Volume(s)
     £0.04 (4 pence) per warrant                                                                         74,656,250

 d)  Aggregated information

     ·       - Aggregated volume                                  n/a

     ·       - Price
 e)  Date of the transaction                                      10 July 2025
 f)  Place of the transaction                                     Outside a trading venue.

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         ZQ Capital Management Limited
 2   Reason for the notification
 a)  Position/status                                              Persons closely associated Mr. Zheqing Shen, Non-Executive Director of Allergy
                                                                  Therapeutics Plc.
 b)  Initial notification/Amendment                               Initial notification.
 3   Details of the issuer, UK emission allowance market participant, auction
     platform or auctioneer
 a)  Name                                                         Allergy Therapeutics Plc
 b)  LEI                                                          213800PQ7AHK7KGVOE23
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Warrant Instrument

 b)  Nature of the transaction                                    Issue of warrants representing subscription rights for ordinary shares of
                                                                  £0.001 each.

 c)  Price(s) and volume(s)                                       Exercise Price(s)                         Volume(s)
     £0.04 (4 pence) per warrant                                                                            175,343,750

 d)  Aggregated information

     ·       - Aggregated volume                                  n/a

     ·       - Price
 e)  Date of the transaction                                      10 July 2025
 f)  Place of the transaction                                     Outside a trading venue.

 

 1  As enlarged by the issue of ordinary shares on exercise of the warrants

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSFIFWSEISELW